Organic Active Ingredients TRIZ Cases

Segmenting ACAT1 isoforms enables selective inhibition in macrophages, resolving the trade-off between therapeutic effectiveness and systemic side effects.

Biodegradable polymer fiber delivers clonidine locally to avoid systemic opioid side effects.

Combining HDAC inhibitors with androgen receptor modulators restores skeletal muscle mass in cancer cachexia patients.

Anti-TIM antibodies block phosphatidylserine-mediated viral entry to treat broad-spectrum enveloped viruses.

Prenatal GnRH antagonist administration prevents PCOS transmission to offspring while restoring ovarian function in adults.

Novel 4-heteroarylcarbonyl piperidine carboxamides inhibit tankyrase enzymes to modulate the Wnt signaling pathway.

Segmented star-branched PEG and heparin resolve the trade-off between structural support and cell adhesion versatility.

HPMC-AS solid dispersions of heterocyclic RBP4 inhibitors reduce bisretinoid accumulation and preserve photoreceptor cells.

A 20-nucleotide single-stranded DNA aptamer binds to myelin to promote remyelination.

Segmentation and intermediary principles enable a conjugate that delivers toxins specifically to ROBO1-expressing tumors while sparing normal cells.

Pyrazolo[3,4-b]pyridine compounds inhibit protein kinase C beta by reducing molecular weight while improving selectivity over other isoenzymes.

Deuterated ruxolitinib analogs modulate JAK1 and JAK2 activity, resolving insufficient hair regrowth in alopecia areata.

3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds inhibit WIZ protein expression to induce fetal hemoglobin production.

Dimyricetin-yl-diselenide overcomes safety trade-offs by combining myricetin with selenium to induce apoptosis while reducing oxidative stress.

Dezocine compositions manage neuropathic pain and addiction by reducing respiratory depression risks associated with full agonists.

Intermittent dosing of NMDA antagonists reverses abnormal phenotypes and eliminates apneic breathing by modulating neurotransmission.

An oral aerosol formulation of cytisine with pH adjustment bypasses gastrointestinal side effects to improve patient compliance and treatment effectiveness.

Fourth-generation inhibitors overcome T790M and C797S resistance while sparing wild-type EGFR to reduce on-target toxicities.

Formula I compounds inhibit HIV integrase to treat resistant viral strains failing standard therapies.

Modified steroid compounds enhance FXR and TGR5 receptor activity, resolving poor patient sensitivity in cholestasis treatment.

Combining pyrrolidone carboxylic acid with hyaluronic acid creates a composite formulation that delivers sustained hydration to mucosal tissues.

Inhalable expression vector delivers plasmids directly to lungs, resolving systemic administration limits.

Fluorinated pyrimidine compounds improve metabolic stability and reduce dosing frequency to combat resistant HIV strains.

Bevacizumab combined with chemotherapy extends progression-free survival by three months in platinum-resistant ovarian cancer patients.

Palladium catalyzed synthesis of influenza replication inhibitors overcomes viral mutation resistance.

Extracting capsule polysaccharides from lipooligosaccharides prevents autoimmune responses triggered by molecular mimicry with human gangliosides.

[1,2,4]Triazolo[4,3-a]pyridinyl substituted indole compounds inhibit Toll-like receptor signaling pathways.

UDCA derivatives increase intracellular calcium to inhibit HDAC6 activity in polycystic cholangiocytes.

Pyrazolopyrimidine and imidazopyrazine compounds selectively inhibit apicomplexan CDPKs, sparing mammalian cells while treating toxoplasmosis.

Bicyclic sulfonyl compounds act as hepatoselective LXR inverse agonists to reduce hepatic steatosis without disrupting peripheral reverse cholesterol transport.

A lipid-based gel formulation enhances pirfenidone cutaneous delivery through solubilization and viscosification mechanisms.

Spiro-lactam compounds bind to the glycine site of NMDA receptors, enabling oral delivery while maintaining high therapeutic efficacy.

Pyridone derivatives with fused bicyclic groups modulate epigenetic regulation to treat NUT midline carcinoma and other cancers.

High-loading granulated darunavir tablets reduce pill burden and improve compliance for HIV treatment regimens.

Heterocyclic compounds inhibit A2A and A2B receptors, resolving the trade-off between treatment reliability and targeting specificity in cancer therapy.

Compounds binding KRAS G12C in both nucleotide states overcome resistance from insufficient GTP inhibition.

Compounds prevent cold-induced structural damage to platelets, extending viability beyond standard limits.

Controlling weight average chain length ratios during annealing prevents long chain formation and reduces toxicity in dsRNA adjuvants.

Ibudilast treats macular injury in progressive multiple sclerosis by inhibiting phosphodiesterase enzymes to preserve vision.

Combining a polyamide with prostate agents blocks androgen receptor nuclear translocation, overcoming resistance to enzalutamide therapy.

Acylation transforms oily cannabinoids into crystalline derivatives, preventing decarboxylation during purification.

A preservative-free intranasal lidocaine formulation delivers localized sodium channel blockade via a mechanical multi-dose pump.

A pyrrolo[2,3-d]pyrimidine derivative modulates Janus kinase activity through specific substituent placement.

Hydroxypropyl guar polymer mediates between mucoadhesive agents and emulsion phases, preventing phase separation while enhancing therapeutic delivery.

A transdermal patch diffuses oxymorphone through a pressure-sensitive adhesive layer for sustained skin permeation.